Forest pays AZ $210mm for all rights to Novexel candidate
Following its concurrently announced acquisition of antibiotics developer Novexel, AstraZeneca has agreed to hand over all rights for Novexel's lead broad-spectrum candidate NXL104 to Forest Laboratories for $210mm. The deal sees AZ both granting and receiving rights through what turns out to be a very complex transaction.
- Specialty Pharmaceuticals
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.